T cell receptor alpha variable 19Genealiases: TCRAV12S1 · TCRAV19S1
Q-omics provides the consensus-scored TRAV19 profile across patient tissues and cancer cell-line models. TRAV19 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TRAV19 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, TRAV19 RNA expression shows 16,436 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where TRAV19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAV19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAV19 survival associations across molecular data types. TRAV19 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAV19 RNA expression–survival associations across cancer types. High TRAV19 expression shows unfavorable associations in UVM, but favorable associations in HNSC, BRCA, SKCM, BLCA and UCEC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TRAV19 RNA expression.
This table summarizes TRAV19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAV19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAV19 shows lower tumor expression in COAD, UCEC and LUSC and higher tumor expression in KIRC, KICH and BRCA. The KIRC box plot shows higher TRAV19 RNA expression in tumor versus normal tissue (log2 FC = +1.502, t-test p < 0.001).
This table shows molecular features associated with TRAV19 in patient tissues and cancer cell lines. In patient samples, TRAV19 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
